Too much of a good thing?

See allHide authors and affiliations

Science  23 Mar 2018:
Vol. 359, Issue 6382, pp. 1346-1347
DOI: 10.1126/science.359.6382.1346

You are currently viewing the summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution


As the growing wave of excitement over immunotherapies has swept through the cancer field, a concern has arisen in its wake. Are there now too many clinical trials for these novel treatments, which enlist the immune system to battle tumors? One recent tally found more than 1100 studies combining a popular new class called checkpoint inhibitor drugs, which unleash suppressed immune cells, with other treatments. Some academic researchers, pharma executives, and other experts have decried this explosion of trials as a counterproductive glut motivated more by the race for money than good science and warned that many of these efforts may not finish because of a lack of participants. Other researchers, however, think the competition is healthy—and that the best studies and combos will prevail.